drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy. Patient T cells are genetically engineered to express a CAR (with CD3ζ and costimulatory domains) that binds CD19; engagement triggers T-cell activation, proliferation, and perforin/granzyme-mediated cytotoxicity, eliminating CD19+ malignant B cells and causing expected B-cell aplasia. Administered by intravenous autotransfusion for relapsed/refractory CD19+ B-ALL/B-lymphoblastic lymphoma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a CD19-specific chimeric antigen receptor containing CD3ζ and costimulatory domains. Upon binding CD19 on malignant B cells, the CAR triggers T-cell activation, expansion, and perforin/granzyme-mediated cytotoxicity, eliminating CD19+ cells and causing on‑target B‑cell aplasia.
drug_name
BIC-19GG
nct_id_drug_ref
NCT06355739